Acute myeloid leukemia trials in Netherlands

In Netherlands 26 Also abroad 761

26 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Where
Amersfoort, Amsterdam, Arnhem, Breda, Dordrecht, Eindhoven, Groningen, Leeuwarden, Leiden, Maastricht, Nieuwegein, Nijmegen, Rotterdam, 's-Gravenhage, 'S-Hertogenbosch, Utrecht, Zwolle
Age
18 years and over
People
875 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07223814 · EU 2025-522767-15-00
Phase 1Taking people
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
Where
Groningen, Rotterdam
Age
18 years and over
People
40 worldwide
Run by
Charm Therapeutics
See details and how to joinNCT07751991 · EU 2026-526409-14-00
Phase 1Taking people
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Where
Groningen, Rotterdam
Age
18 years and over
People
78 worldwide
Run by
Genmab
See details and how to joinNCT07384715 · EU 2025-523101-15-00
Phase 3Taking people
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Where
Amersfoort, Amsterdam, Arnhem, Breda, Delft, Den Bosch, Den Haag, Dordrecht, Eindhoven, Enschede, Groningen, Leeuwarden, Leiden, Maastricht, Nieuwegein, Nijmegen, Rotterdam, Utrecht, Zwolle
Age
18 years to 75 years
People
650 worldwide
Run by
University of Ulm
See details and how to joinNCT04628026 · EU 2023-507518-28-00
Phase 3Taking people
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
Where
Amsterdam, Arnhem, Breda, Dordrecht, Eindhoven, Enschede, Geleen, Groningen, Nijmegen, Rotterdam, 's-Gravenhage, 'S-Hertogenbosch, Utrecht, Zwolle
Age
18 years and over
People
180 worldwide
Run by
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2024-512753-24-00 · EU 2024-512753-24-00
Phase 3Taking people
Teicoplanin as Infection Prophylaxis in Pediatric Acute Myeloid Leukemia (Pro-Teico study)
Where
Utrecht
Age
Up to 64 years
People
128 worldwide
Run by
Prinses Maxima Centrum voor Kinderoncologie B.V.
See details and how to join2023-506546-23-00 · EU 2023-506546-23-00
Phase 1/2Taking people
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Where
Utrecht
Age
1 year to 17 years
People
70 worldwide
Run by
Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00
Phase 1/2Taking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
Utrecht
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 1Taking people
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Where
Utrecht
Age
0 years to 21 years
People
20 worldwide
Run by
PedAL BCU, LLC
See details and how to joinNCT06376162 · EU 2023-505262-28-00
Phase 1Taking people
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
Where
Amsterdam, Rotterdam
Age
18 years and over
People
37 worldwide
Run by
AvenCell Europe GmbH
See details and how to joinNCT05949125 · EU 2022-501797-19-00
Phase 3Taking people
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
Where
Utrecht
Age
Up to 64 years
People
675 worldwide
Run by
Prinses Maxima Centrum voor Kinderoncologie B.V.
See details and how to join2023-504999-25-00 · EU 2023-504999-25-00
Phase 2Taking people
A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML
Where
Amersfoort, Amsterdam, Arnhem, Breda, Dordrecht, Eindhoven, Enschede, Groningen, Leeuwarden, Leiden, Maastricht, Nieuwegein, Nijmegen, 's-Gravenhage, 'S-Hertogenbosch, Veldhoven, Zwolle
Age
18 years and over
People
142
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06014489 · EU 2023-505379-61-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Groningen
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 3Taking people
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Where
Amersfoort, Amsterdam, Arnhem, Breda, Delft, Dordrecht, Eindhoven, Enschede, Goes, Groningen, Leeuwarden, Leiden, Maastricht, Nieuwegein, Nijmegen, Rotterdam, 's-Gravenhage, 'S-Hertogenbosch, Utrecht, Zwolle
Age
18 years and over
People
448 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06652438 · EU 2024-512733-32-00
Phase 2Taking people
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
Where
Utrecht
Age
Up to 64 years
People
31 worldwide
Run by
Pediatric Research International GmbH
See details and how to join2025-521390-14-00 · EU 2025-521390-14-00
Phase 1/2Not yet taking people in Netherlands
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
Where
Amsterdam, Groningen, Maastricht, Nijmegen
Age
18 years and over
People
64 worldwide
Run by
Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00
Phase 1/2Taking people
Study to Evaluate the Safety and Tolerability of EP0042
Where
Amsterdam, Rotterdam
Age
18 years and over
People
70 worldwide
Run by
Ellipses Pharma
See details and how to joinNCT04581512 · EU 2024-514588-24-00
Phase 3Taking people
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Where
Amsterdam, Groningen
Age
18 years and over
People
245 worldwide
Run by
Servier Affaires Médicales
See details and how to joinNCT05907057 · EU 2022-501709-11-00
Phase 1/2Taking people
MB-dNPM1-TCR.1 in Relapsed/Refractory AML
Where
Leiden
Age
18 years and over
People
29
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT06424340
Phase 1/2Taking people
A study of the safety and efficacy of MB-dNPM-1-TCR.1 in patients with relapsed or refractory AML.
Where
Leiden
Age
18 years and over
People
32
Run by
Miltenyi Biomedicine GmbH
See details and how to join2023-505806-41-00 · EU 2023-505806-41-00
Phase 3Taking people
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Where
Amsterdam, Arnhem, Breda, Dordrecht, Eindhoven, Enschede, Geleen, Groningen, Nijmegen, Rotterdam, 's-Hertogenbosch, The Hague, Utrecht, Zwolle
Age
18 years and over
People
227 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07075016
Phase 3Taking people
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients
Where
Utrecht
Age
1 day to 18 years
People
905
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05994690
Phase 2Taking people
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
Where
Utrecht
Age
1 month to 18 years
People
60 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT06262438 · EU 2023-505000-27-01
Phase 3Taking people
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
Where
Utrecht
Age
Up to 18 years
People
170 worldwide
Run by
Vastra Gotaland Region
See details and how to joinNCT05477589
Phase 3Taking people
NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years
Where
Utrecht
Age
Up to 64 years
People
730 worldwide
Run by
Vaestra Goetalandsregionen
See details and how to joinNCT01828489 · EU 2024-518254-16-00